Which laboratory tests should be obtained and how often monitored when initiating fludrocortisone (Florinef) therapy?

Laboratory Monitoring for Fludrocortisone (Florinef) Therapy

Monitor serum electrolytes (sodium and potassium) and blood pressure regularly when initiating fludrocortisone, with the FDA label mandating "regular" blood pressure determinations and "periodic" serum electrolyte checks, while the 2016 Endocrine Society guidelines recommend primarily clinical assessment supplemented by blood electrolyte measurements. 1, 2

Initial Laboratory Tests

When starting fludrocortisone therapy, obtain:

• Baseline serum electrolytes (sodium and potassium)
• Baseline blood pressure (sitting and standing positions to assess for orthostatic hypotension)
• Plasma renin activity (optional but useful - target upper reference range) 2

Monitoring Frequency

Early Phase (First 1-3 Months)

The FDA label requires "frequent intervals" for potassium monitoring, particularly when fludrocortisone is combined with potassium-depleting drugs 1. In practical terms:

• Serum electrolytes every 2-4 weeks initially until stable
• Blood pressure at each visit (both sitting and standing)
• Watch for hypokalemia (develops in approximately 24% of patients at mean of 8 months) 3

Maintenance Phase

Once stable on therapy:

• Serum electrolytes every 3-6 months 2
• Blood pressure monitoring at each clinical visit
• More frequent monitoring if dose adjustments are made or during intercurrent illness

Clinical Assessment Takes Priority

The Endocrine Society guidelines emphasize that monitoring should be "primarily based on clinical assessment" rather than laboratory values alone 2. Assess for:

• Salt craving (suggests under-replacement)
• Postural hypotension/dizziness (suggests under-replacement)
• Peripheral edema (suggests over-replacement, though low sensitivity)
• Hypertension (suggests over-replacement)
• Weight gain (suggests over-replacement)

Critical Monitoring Considerations

Hypokalemia Risk

The FDA label specifically warns about enhanced hypokalemia risk when fludrocortisone is combined with 1:

• Amphotericin B
• Potassium-depleting diuretics (thiazides, furosemide, ethacrynic acid)
• Digitalis glycosides (increased arrhythmia risk)

Check potassium levels at frequent intervals and use supplements if necessary when these drugs are co-administered.

Hypertension Development

If hypertension develops during therapy 2:

1. First step: Reduce fludrocortisone dose
2. If blood pressure remains uncontrolled: Add antihypertensive therapy while continuing fludrocortisone (don't discontinue the mineralocorticoid replacement)

Plasma Renin Activity

While not mandatory, plasma renin activity in the upper reference range indicates optimal mineralocorticoid dosing 2. This can be particularly useful when clinical assessment is equivocal or when fine-tuning therapy.

Common Pitfalls to Avoid

1. Don't rely solely on laboratory values - Clinical assessment is paramount. Patients with normal electrolytes may still be under- or over-replaced based on symptoms and blood pressure 2

2. Don't discontinue fludrocortisone for hypertension without first attempting dose reduction - Many patients need continued mineralocorticoid replacement even if they develop hypertension 2

3. Don't forget orthostatic blood pressure measurements - Sitting blood pressure alone may miss postural hypotension indicating under-replacement 2

4. Monitor more frequently during dose adjustments, hot weather, or illness - These situations may require temporary dose changes 2

5. In elderly patients, be aware of poor long-term tolerance - One study showed 33% discontinued fludrocortisone at mean of 5 months due to adverse effects (hypertension, heart failure, edema) 3